Research summary
Studies focus on randomized renal and cardiovascular trials in diabetic nephropathy and chronic kidney disease, mechanistic and therapeutic studies of thrombotic microangiopathies, and population-level renal-cardiovascular epidemiology. The RENAAL trial randomized 1,513 patients with type 2 diabetes and nephropathy to losartan (50-100 mg daily) or placebo added to conventional antihypertensive therapy in a double-blind comparison of renal and cardiovascular outcomes, addressing the gap in evidence for angiotensin-II-receptor antagonism in type 2 diabetes [1]. The TREAT trial randomized 4,038 patients with type 2 diabetes, chronic kidney disease, and anemia to darbepoetin alfa (targeting hemoglobin near 13 g/dL) or placebo with rescue darbepoetin when hemoglobin fell below 9.0 g/dL, testing whether anemia correction improves clinical outcomes [3]. The AURORA trial randomized 2,776 maintenance-hemodialysis patients aged 50-80 to rosuvastatin 10 mg daily or placebo, with the composite primary endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, testing statin efficacy in dialysis populations [4]. Two phase 2 trials of eculizumab in atypical hemolytic-uremic syndrome enrolled patients aged 12 or older for 26 weeks of treatment plus long-term extension, with one trial enrolling patients with low platelet counts and renal damage and the other patients with renal damage but stable platelets despite at least 8 weeks of plasma exchange or infusion [6]. Plasma samples from 53 patients with thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome were assayed with purified normal plasma to determine the prevalence of von Willebrand factor-cleaving protease deficiency in familial and nonfamilial forms [5]. A review on atypical hemolytic-uremic syndrome described pathobiology, diagnosis, and management of the complement-dysregulation-driven thrombotic microangiopathy that accounts for about 10% of HUS cases without infection [8]. A review of organoid models traced the evolution from classical reaggregation experiments to 3D self-organizing stem-cell-derived structures with applications in development and disease modeling [2]. A systematic review and meta-analysis of European studies quantified gender-specific differences in office systolic and diastolic blood pressure among Sub-Saharan African, South Asian, and native European adults [7].
Recent publications
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyDOI
- Organoid Models and Applications in Biomedical ResearchDOI
- COVID-19 and Italy: what next?DOI
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseDOI
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisDOI
- von Willebrand Factor鈥揅leaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic鈥揢remic SyndromeDOI
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic鈥揢remic SyndromeDOI
- The contribution of chronic kidney disease to the global burden of major noncommunicable diseasesDOI
- Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-AnalysisDOI
- Atypical Hemolytic鈥揢remic SyndromeDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email Giuseppe Remuzzi 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0002-6194-3446
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, The University of Tokyo faculty directory). Last refreshed 2026-05. Report incorrect information.